Adicon Holdings (HKSE:09860) ROCE % : 10.88% (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Adicon Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Adicon Holdings's annualized ROCE % for the quarter that ended in Jun. 2024 was 10.88%.

Adicon Holdings ROCE % Historical Data

The historical data trend for Adicon Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicon Holdings ROCE % Chart

Adicon Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

22.04

25.64

40.90

16.49

Adicon Holdings Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			49.58	35.99	15.17	17.26	10.88

Adicon Holdings ROCE % Calculation

Adicon Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	476.546	/	( ( (5420.793 - 2700.699)	+	(4980.564 - 1921.789) )	/ 2 )
	=	476.546	/	( (2720.094	+	3058.775)	/ 2 )
	=	476.546	/	2889.4345
	=	16.49 %

Adicon Holdings's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	347.008	/	( ( (4980.564 - 1921.789)	+	(5016.331 - 1698.199) )	/ 2 )
	=	347.008	/	( ( 3058.775	+	3318.132 )	/ 2 )
	=	347.008	/	3188.4535
	=	10.88 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Adicon Holdings (HKSE:09860) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Adicon Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Adicon Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicon Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Adicon Holdings Ltd (HKSE:09860) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 208, Zhenzhong Road, West Lake, Zhejiang, Hangzhou, CHN

Website

https://www.adicon.com.cn

Founded in 2004 and listing on the Hong Kong Exchange in 2023, Adicon is one of the largest independent clinical laboratories in China. In October 2018, private equity Carlyle Group completed its investment in Adicon and has since been the largest single shareholder. Following Carlyle's investment, Adicon quickly stepped up its footprint. It has a testing portfolio of over 4,000 medical diagnostic tests with 36 self-operated laboratories in 2023, compared with 1,800 items and 21 labs in 2018. Currently, esoteric tests account for nearly 60% of its testing portfolio. Esoteric tests require more specialized technologies and/or equipment.

Executives

Cap V General Partner, L.p.	2201 Interest of corporation controlled by you
Cap V, L.l.c.	2201 Interest of corporation controlled by you
Carlyle Asia Partners V, L.p.	2201 Interest of corporation controlled by you
Carlyle Holdings Ii Gp L.l.c.	2201 Interest of corporation controlled by you
Carlyle Holdings Ii L.l.c.	2201 Interest of corporation controlled by you
Cg Subsidiary Holdings L.l.c.	2201 Interest of corporation controlled by you
Pearl Group Limited	2101 Beneficial owner
Tc Group Cayman Investment Holdings L.p.	2201 Interest of corporation controlled by you
Tc Group Cayman Investment Holdings Sub L.p.	2201 Interest of corporation controlled by you
The Carlyle Group Inc.	2201 Interest of corporation controlled by you
Lin Feng
Mega Stream Limited
Trident Trust Company (hk) Limited	2301 Trustee
Ingenuity Capital Holdings Limited	2201 Interest of corporation controlled by you
Corelink Group Limited

Adicon Holdings Headlines

No Headlines